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A recent publication inNature by North et al. (2007) has implicated the eicosanoid prostaglandin E2 in
enhancement of hematopoietic stem cell function in zebrafish and in mice. This work may have
practical therapeutic value, but much remains to be determined before this possibility is realized.Hematopoiesis is a dynamic process,
regulated in part by soluble molecules
(Shaheen and Broxmeyer, 2007) and
beginning at the level of a long-term
repopulating (LTR), competitive (C),
and self-renewing (SR) hematopoietic
stem cell (HSC) (Broxmeyer et al.,
2006; Kondo et al., 2003). Studies in
the mid 1970s implicated the eicosa-
noid prostaglandin E (PGE) in modula-
tion of hematopoiesis at the level of
mature subsets of HSC (e.g., spleen
colony-forming unit, CFU-S) (Feher
and Gidali, 1974) with more extensive
studies assessing effects of PGE1
and -2 on lineage-restricted hemato-
poietic progenitor cells (HPC) using
in vitro colony-forming assays (Pelus
et al., 1979; Lu et al., 1986). In the
last 20 years, few new insights have
evolved on hematopoietic effects me-
diated by PGE. North and colleagues
have now revitalized this area by impli-
cating PGE2 and its production in the
modulation of homeostasis of verte-
brate HSC (North et al., 2007). They
came upon a role for PGE2 in LTR/C-
HSC function through a screening pro-
cess in which a panel of biologically
active compounds was assessed for
induction of stem cell expansion in
zebrafish. Chemicals that enhanced
synthesis of PGE2 increased HSC
function; those that blocked PG syn-
thesis decreased HSC function. More-
over, a stable derivative of PGE2, 16,
16-dimethyl (dm) PGE2, enhanced
kidney marrow recovery in irradiation-
induced injury in adult zebrafish. A
similar capacity for PGE2 was ob-
served in mammals, in that exposure
ofmurine bonemarrow to dmPGE2 in-
creased the repopulation capacity ofthese cells in a transplant setting. Of
note, dm PGE2 treatment of bone
marrow cells elevated the function of
HSCs without inducing a specific
expansion of LTR/C-HSCs, despite
this having been the basis for the orig-
inal screen in the zebrafish system.
HSC transplantation is a critical
component of certain treatment
modalities to cure a wide range of
malignant and nonmalignant blood
disorders. However, numbers of donor
HSCs are sometimes limiting, espe-
cially for transplantation of adults or
higher-weight children when umbilical
cord blood is the source of donor
HSCs (Broxmeyer, 2006). Efforts to
ex vivo expand human HSCs for ther-
apy have not been successful (Brox-
meyer, 2006). North et al. (2007) envi-
sion a scenario in which modulation
of the PG pathway can enhance
expansion of HSCs for therapeutic
use (North et al., 2007). Whether or
not PGE2, modified PGE2, or modula-
tion of PG production will prove effec-
tive for expanding LTR/C/SR-HSC
remains to be determined. The authors
treated whole mouse bone marrow
with dm PGE2 ex vivo for 2 hr prior to
quantitating by in vivo analysis the
number of day 12 CFU-S (a stem cell
not considered to have LTRHSC activ-
ity) and frequency of LTR/C-HSC
(North et al., 2007). This resulted in
an approximately 3-fold increase in
day 12 CFU-S and a 4- to 5-fold
enhancement in HSC frequency at 6–
12 weeks. It is remarkable that a signif-
icant elevation of HPC and HSC activ-
ity was achieved during only 2 hr of
exposure to dm PGE2. It is unlikely
that any expansion of HSC numberCell Stem Ceoccurred within the 2 hr of ex vivo
treatment and before the cells were
transplanted. How, then, was the im-
pact on HSC function mediated, and
what role was played in vivo versus
in vitro? Was a direct effect on the
HSC imparted by division or ‘‘prim-
ing,’’ or through PGE2 effects medi-
ated by accessory cells, or by an indi-
rect effect on nonhematopoietic cells
within the treated cell population,
such as endothelial cells or their pro-
genitors?
PGE2 has a number of effects on
HPC. PGE2 has myelosuppressive ef-
fects on CFU-M/GM (Pelus et al.,
1979) and can enhance colony forma-
tion by erythroid (BFU-E) progenitors,
effects mediated by T cells (Lu et al.,
1986). Proof of direct PGE2 actions
on HSC will be difficult to attain but
would have to entail functional studies
on single purified HSC. An initial step in
this direction was performed by North
and colleagues, in that a purified pop-
ulation, enriched for HSC and HPC
cells, also exhibited elevated CFU-S
potential following in vitro exposure
to dm PGE2. It is possible that the en-
hancing effects of PGE on day 12
CFU-S and HSC may result from
PGE-induced modulation of HSC
homing. The authors suggested that
changes in homing efficiency were
not involved (North et al., 2007). How-
ever, the authors used mixed popula-
tions of cells in their assay, and to ob-
tain definite proof regarding the impact
on homing will require the assessment
of purified populations of cells.
Of note, the largest enhancement in
HSC frequency was apparent 6 and
12 weeks posttransplantation, withll 1, August 2007 ª2007 Elsevier Inc. 135
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quency observed at 24 weeks. This
could be interpreted as dm PGE2 hav-
ing a greater enhancing effect on
shorter- versus longer-term repopulat-
ing HSCs. Such activity would still be
important, as an enhancement of
short-term function with at least main-
tenance of LTR cells would be of po-
tential clinical value. Secondary trans-
plant studies, in which marrow cells
from primary repopulated mice are
transplanted into secondary irradiated
recipients, would help determine if
PGE2 effects were on an SR popula-
tion of HSC or perhaps if the process
of SR was being influenced.
Ex vivo expansion for clinical use is
usually done by incubation of cells
in vitro for days. It is hard to predict
what effects, if any, dm PGE2 would
have on such ex vivo cultures of LTR/
C/SR-HSC. Moreover, these effects
may differ depending on the composi-
tion of cell types in culture. Apprecia-136 Cell Stem Cell 1, August 2007 ª2007tion of which of the four different PGE
receptors mediate the above effects
could shed light on PGE2 function at
a cellular and intracellular level. How-
ever, in clinical transplantation, sim-
pler is better. The ability of dm PGE2
to manifest its effect within 2 hr could
have great clinical efficacy, regardless
of the mechanism of action.
The work of North et al. (2007)
should invigorate interest in PGE
modulation of hematopoiesis. We
look forward with anticipation to fur-
ther studies of PGE effects on HSC
and ESC. Such studies should take
us closer to realizing the potential for
PGE modulation of stem cells for clini-
cal utility.
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